Biomet subpoena
This article was originally published in The Gray Sheet
Executive Summary
Orthopedic firm and U.S. Attorney's office in New Jersey begin discussions of a potential resolution to a Department of Justice investigation into Biomet's relationships with surgeons, the firm discloses in a July 9 SEC filing. Justice has been looking into Biomet's consulting and professional service agreements, as well as research agreements and other grants, with potential orthopedic surgeon customers for the company's hip and knee implants from 1998 to the present (1"The Gray Sheet" June 25, 2007, p. 13). "The results of any resolution remain uncertain at this time, but could, among other things, require monetary payments, cause the company to significantly change some of its existing business practices, and include the potential for additional governmental oversight," Biomet says...
You may also be interested in...
When Corporate Integrity Agreements Multiply, Firms Know What To Expect
Orthopedic companies will likely be among the next device firms subject to corporate integrity agreements with the HHS Office of Inspector General, and stakeholders say there are clues as to what they should expect
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.